Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,403 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy.
Nelde A, Kowalewski DJ, Backert L, Schuster H, Werner JO, Klein R, Kohlbacher O, Kanz L, Salih HR, Rammensee HG, Stevanović S, Walz JS. Nelde A, et al. Among authors: klein r. Oncoimmunology. 2018 Feb 14;7(4):e1316438. doi: 10.1080/2162402X.2017.1316438. eCollection 2018. Oncoimmunology. 2018. PMID: 29632711 Free PMC article.
The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy.
Bilich T, Nelde A, Bichmann L, Roerden M, Salih HR, Kowalewski DJ, Schuster H, Tsou CC, Marcu A, Neidert MC, Lübke M, Rieth J, Schemionek M, Brümmendorf TH, Vucinic V, Niederwieser D, Bauer J, Märklin M, Peper JK, Klein R, Kohlbacher O, Kanz L, Rammensee HG, Stevanović S, Walz JS. Bilich T, et al. Among authors: klein r. Blood. 2019 Feb 7;133(6):550-565. doi: 10.1182/blood-2018-07-866830. Epub 2018 Dec 10. Blood. 2019. PMID: 30530751 Free article.
A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer.
Rammensee HG, Wiesmüller KH, Chandran PA, Zelba H, Rusch E, Gouttefangeas C, Kowalewski DJ, Di Marco M, Haen SP, Walz JS, Gloria YC, Bödder J, Schertel JM, Tunger A, Müller L, Kießler M, Wehner R, Schmitz M, Jakobi M, Schneiderhan-Marra N, Klein R, Laske K, Artzner K, Backert L, Schuster H, Schwenck J, Weber ANR, Pichler BJ, Kneilling M, la Fougère C, Forchhammer S, Metzler G, Bauer J, Weide B, Schippert W, Stevanović S, Löffler MW. Rammensee HG, et al. Among authors: klein r. J Immunother Cancer. 2019 Nov 15;7(1):307. doi: 10.1186/s40425-019-0796-5. J Immunother Cancer. 2019. PMID: 31730025 Free PMC article.
Defibrotide for the Treatment of Pediatric Inflammatory Multisystem Syndrome Temporally Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 2 Pediatric Patients.
Lang P, Eichholz T, Bakchoul T, Streiter M, Petrasch M, Bösmüller H, Klein R, Rabsteyn A, Lang AM, Adams C, Klingel K, Gessner M, Rosenberger P, Ruef P, Handgretinger R. Lang P, et al. Among authors: klein r. J Pediatric Infect Dis Soc. 2020 Nov 10;9(5):622-625. doi: 10.1093/jpids/piaa117. J Pediatric Infect Dis Soc. 2020. PMID: 32951037 Free PMC article.
SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition.
Nelde A, Bilich T, Heitmann JS, Maringer Y, Salih HR, Roerden M, Lübke M, Bauer J, Rieth J, Wacker M, Peter A, Hörber S, Traenkle B, Kaiser PD, Rothbauer U, Becker M, Junker D, Krause G, Strengert M, Schneiderhan-Marra N, Templin MF, Joos TO, Kowalewski DJ, Stos-Zweifel V, Fehr M, Rabsteyn A, Mirakaj V, Karbach J, Jäger E, Graf M, Gruber LC, Rachfalski D, Preuß B, Hagelstein I, Märklin M, Bakchoul T, Gouttefangeas C, Kohlbacher O, Klein R, Stevanović S, Rammensee HG, Walz JS. Nelde A, et al. Among authors: klein r. Nat Immunol. 2021 Jan;22(1):74-85. doi: 10.1038/s41590-020-00808-x. Epub 2020 Sep 30. Nat Immunol. 2021. PMID: 32999467
Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups.
Rammensee HG, Gouttefangeas C, Heidu S, Klein R, Preuß B, Walz JS, Nelde A, Haen SP, Reth M, Yang J, Tabatabai G, Bösmüller H, Hoffmann H, Schindler M, Planz O, Wiesmüller KH, Löffler MW. Rammensee HG, et al. Among authors: klein r. Vaccines (Basel). 2021 Apr 24;9(5):428. doi: 10.3390/vaccines9050428. Vaccines (Basel). 2021. PMID: 33923363 Free PMC article.
Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer.
Bilich T, Roerden M, Maringer Y, Nelde A, Heitmann JS, Dubbelaar ML, Peter A, Hörber S, Bauer J, Rieth J, Wacker M, Berner F, Flatz L, Held S, Brossart P, Märklin M, Wagner P, Erne E, Klein R, Rammensee HG, Salih HR, Walz JS. Bilich T, et al. Among authors: klein r. Cancer Discov. 2021 Aug;11(8):1982-1995. doi: 10.1158/2159-8290.CD-21-0191. Epub 2021 May 19. Cancer Discov. 2021. PMID: 34011563
5,403 results